Literature DB >> 22278757

Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.

Eriko Ogusa1, Naoto Tomita, Yoshimi Ishii, Hirotaka Takasaki, Yukako Hattori, Chihiro Matsumoto, Yoshiaki Ishigatsubo.   

Abstract

We retrospectively analysed 16 cases of newly diagnosed pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in the Japanese population. The disease was found on the basis of examination findings in 14 cases, and clinical manifestations in 2. According to the extensive staging procedure, four patients had concomitant gastric involvement. Primary treatment involved surgery alone in two patients; surgery followed by rituximab (R)-containing chemotherapy in two; R-containing chemotherapy alone in 11; and chemoradiotherapy without R in one. Over the median observation period of 28 months, disease progression was recorded in three patients, but all 16 patients were alive at the end of the observation period. One patient was treated with R alone and achieved partial remission; subsequent tentative surgery showed no evidence of residual lymphoma. It has been 72 months of progression-free survival after the diagnosis. Primary pulmonary MALT lymphoma exhibited an indolent clinical course. R has potential as a therapeutic agent in patients with pulmonary MALT lymphoma.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278757     DOI: 10.1002/hon.2008

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  5 in total

1.  Diagnostic and prognostic factors for patients with primary pulmonary non-Hodgkin's lymphoma: A 16-year single-center retrospective study.

Authors:  Jiang Qian; Dong-Lan Luo; Jin-E Zhang; Wen-Yu Li; Xing-Lin Gao; Xiang-Feng Fang; Hong An; Jun-Liang Deng; Qiong Li; Jian Wu
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

2.  Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study.

Authors:  Wei Yan; Bin Wu; Ai-Jun Liao; Wei Yang; Hui-Han Wang
Journal:  Ann Hematol       Date:  2021-01-22       Impact factor: 3.673

3.  Prolonged complete remission in a primary MALT lymphoma of the lung after rituximab monotherapy.

Authors:  M D Diamantidis; S Chatzileontiadou; D Pantelidou; M Papaioannou
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

4.  Bulky pulmonary mucosa-associated lymphoid tissue lymphoma treated with yttrium-90 ibritumomab tiuxetan.

Authors:  Shinobu Tamura; Tokuji Ikeda; Toshio Kurihara; Yoshiteru Kakuno; Hideki Nasu; Yoshio Nakano; Koichi Oshima; Tokuzo Fujimoto
Journal:  Case Rep Hematol       Date:  2013-11-26

5.  Clinical manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma: single-center experience with 18 patients.

Authors:  Shasha Zhao; Lin Zhang; Zhenyang Gu; Chengying Zhu; Shu Fang; Nan Yang; Feiyan Wang; Lixun Guan; Lan Luo; Chunji Gao
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.